JP2022530322A5 - - Google Patents
Info
- Publication number
- JP2022530322A5 JP2022530322A5 JP2021559917A JP2021559917A JP2022530322A5 JP 2022530322 A5 JP2022530322 A5 JP 2022530322A5 JP 2021559917 A JP2021559917 A JP 2021559917A JP 2021559917 A JP2021559917 A JP 2021559917A JP 2022530322 A5 JP2022530322 A5 JP 2022530322A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- alkyl
- acceptable salt
- solvate
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835963P | 2019-04-18 | 2019-04-18 | |
| US62/835,963 | 2019-04-18 | ||
| PCT/IB2020/000288 WO2020212755A1 (en) | 2019-04-18 | 2020-04-16 | Compounds and methods for the treatment of ocular disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530322A JP2022530322A (ja) | 2022-06-29 |
| JP2022530322A5 true JP2022530322A5 (https=) | 2024-03-26 |
| JP7700045B2 JP7700045B2 (ja) | 2025-06-30 |
Family
ID=72832983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559917A Active JP7700045B2 (ja) | 2019-04-18 | 2020-04-16 | 眼障害を処置するための化合物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10875845B2 (https=) |
| EP (1) | EP3955926A4 (https=) |
| JP (1) | JP7700045B2 (https=) |
| KR (1) | KR20220003555A (https=) |
| CN (1) | CN114025759A (https=) |
| IL (1) | IL287264A (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7700045B2 (ja) * | 2019-04-18 | 2025-06-30 | アズーラ オフサルミックス エルティーディー． | 眼障害を処置するための化合物および方法 |
| IL302175A (en) * | 2020-10-21 | 2023-06-01 | Azura Ophthalmics Ltd | Compounds and methods for the treatment of ocular disorders |
| EP4232034A4 (en) * | 2020-10-21 | 2024-12-04 | Azura Ophthalmics Ltd | COMPOUNDS AND METHODS FOR TREATING EYE DISORDERS |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| EP4419502A4 (en) * | 2021-10-20 | 2025-10-29 | Azura Ophthalmics Ltd | COMPOUNDS AND METHODS FOR THE TREATMENT OF SKIN AND OCULAR DISORDERS |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US7056893B2 (en) | 1999-03-31 | 2006-06-06 | Insite Vision, Inc. | Topical treatment for prevention of ocular infections |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| EP1483579A4 (en) | 2002-02-15 | 2006-07-12 | Merckle Gmbh | CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, PROCESS FOR THEIR MANUFACTURE AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF |
| CA2544678C (en) | 2003-11-05 | 2013-12-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
| DK2444079T3 (en) | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| DE102005062987A1 (de) | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| WO2009128934A1 (en) * | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| US20090257957A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders |
| WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| KR20200108932A (ko) * | 2012-07-25 | 2020-09-21 | 에스에이알코드 바이오사이언스 인코포레이티드 | Lfa-1 저해제 및 그의 다형체 |
| BR112015014367B1 (pt) * | 2012-12-19 | 2022-11-22 | Novartis Ag | Composição inibidora de lfa-1, método para estabilizar a dita composição e uso da mesma para tratar uma doença ocular |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| JP2019513775A (ja) | 2016-04-19 | 2019-05-30 | アズーラ オフサルミックス エルティーディー． | 角化症の処置のための組成物 |
| WO2018161039A1 (en) | 2017-03-03 | 2018-09-07 | Synovo Gmbh | Novel anti-infective and anti-inflammatory compounds |
| EP3600272A4 (en) | 2017-03-29 | 2021-01-13 | Azura Ophthalmics Ltd. | MEANS OF INCREASING LIPID SECRETION OF THE MEIBOMAN GLAND |
| WO2019053607A1 (en) * | 2017-09-18 | 2019-03-21 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING LIFITEGRAST |
| EP3955937A4 (en) | 2019-04-18 | 2023-01-18 | Azura Ophthalmics Ltd. | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES |
| WO2020212755A1 (en) | 2019-04-18 | 2020-10-22 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
| JP7700045B2 (ja) | 2019-04-18 | 2025-06-30 | アズーラ オフサルミックス エルティーディー． | 眼障害を処置するための化合物および方法 |
| IL302173A (en) | 2020-10-21 | 2023-06-01 | Azura Ophthalmics Ltd | Compounds and methods for the treatment of ocular disorders |
| US11459351B1 (en) | 2021-04-05 | 2022-10-04 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of ocular disorders |
-
2020
- 2020-04-16 JP JP2021559917A patent/JP7700045B2/ja active Active
- 2020-04-16 KR KR1020217037591A patent/KR20220003555A/ko not_active Ceased
- 2020-04-16 EP EP20791787.3A patent/EP3955926A4/en active Pending
- 2020-04-16 CN CN202080044807.9A patent/CN114025759A/zh active Pending
- 2020-06-17 US US16/904,036 patent/US10875845B2/en active Active
- 2020-12-04 US US17/112,371 patent/US11634411B2/en active Active
-
2021
- 2021-10-14 IL IL287264A patent/IL287264A/en unknown
-
2023
- 2023-03-08 US US18/119,248 patent/US20230357207A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022530322A5 (https=) | ||
| JP5524181B2 (ja) | 治療剤としての置換ガンマラクタム | |
| JP2022529315A5 (https=) | ||
| JP2020521767A5 (https=) | ||
| JP6270848B2 (ja) | ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下 | |
| JP2012525437A5 (https=) | ||
| JP2011507878A5 (https=) | ||
| JP6261011B2 (ja) | 眼疾患処置薬 | |
| JP2011510965A (ja) | 高眼圧症の治療のためのジフルオロビフェニルアミド誘導体 | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2022509206A5 (https=) | ||
| US9150537B2 (en) | Bicyclic compound and use thereof for medical purposes | |
| KR20130029049A (ko) | 아데노신 화합물 및 이의 용도 | |
| JP2016513707A (ja) | 眼神経保護を与える方法 | |
| EP0777669A1 (en) | 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol succinate as antiviral agent | |
| JP2011515406A (ja) | 治療用の置換シクロペンタン類 | |
| KR20100101097A (ko) | 프로스타글란딘 활성을 갖는 치환된 사이클로펜탄 | |
| RU2019111188A (ru) | Кетоновые ингибиторы лизин-специфичного гингипаина | |
| WO2005007161A1 (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
| JP2023512823A5 (https=) | ||
| JP2011518834A (ja) | 治療剤としての置換ガンマラクタム | |
| JP2011515409A (ja) | 治療用化合物 | |
| JP5254007B2 (ja) | 置換β−ラクタム及び医薬におけるその使用 | |
| DK3107906T3 (en) | REDUCED CENTRAL CORNER MAP THICKNESS USING HYDROFILE ESTER PRODRUGS OF BETA-CHLORCYCLOPENTANE | |
| JP2001515897A (ja) | トロンボキサンリガンド |